Brief: Scynexis completes transfer of Brexafemme New Drug Application To GSK
19/11/2025 12:11
Nov 19 (Reuters) - SCYNEXIS Inc SCYX.O: SCYNEXIS COMPLETES TRANSFER OF BREXAFEMME® NEW DRUG APPLICATION TO GSK SCYNEXIS INC - TO RECEIVE UP TO $145.5 MILLION IN ANNUAL NET SALES MILESTONES AS WELL AS ROYALTIES Source text: nGNXbXgkRQ Further company coverage: SCYX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview